2018 年 35 巻 5 号 p. 598-600
Recent advances and new findings relating to multiple sclerosis (MS) and related disorders were reviewed. We adopted the studies regarding an effective treatment for progressive MS, composite endpoints in MS clinical trials, risks for progressive multifocal leukoencephalopathy caused by fingolimod and fumarate, a clinical trial on neuromyelitis optica (NMO), and clinical spectrum of myelin oligodendrocyte glycoprotein (MOG) antibody–positive disorders.